CSL Seqirus has welcomed the announcement that neffy adrenaline nasal spray will be listed on the Pharmaceutical Benefits Scheme on 1 July, making the product reimbursed for emergency treatment of anaphylaxis in adults and some children. …
Nasal adrenaline to be added to the PBS for people at risk of anaphylaxis
June 30, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Nasal adrenaline to be added to the PBS for people at risk of anaphylaxis
June 30, 2026 - - Latest News -
When it comes to negotiating with government, trust actions and not words
June 30, 2026 - - Latest News -
Neuren partner secures critical European backing for Rett syndrome therapy
June 30, 2026 - - Australian Biotech -
Disappointment for CSL as Europe recommends reversing approval of therapy
June 30, 2026 - - BioPharma -
Ipsen therapy approved in Australia for rare genetic disorder
June 30, 2026 - - Latest News -
New MSD vaccine listed on national program with expanded eligibility
June 30, 2026 - - Latest News -
A comment that highlights how complexity is making the challenge more challenging
June 29, 2026 - - Latest News